dc.contributor |
Universitat de Barcelona |
dc.contributor.author |
Novick, Diego |
dc.contributor.author |
Montgomery, William |
dc.contributor.author |
Haro Abad, Josep Maria |
dc.contributor.author |
Moneta, Maria Victoria |
dc.contributor.author |
Zhu, Gang |
dc.contributor.author |
Yue, Li |
dc.contributor.author |
Hong, Jihyung |
dc.contributor.author |
Dueñas, Héctor |
dc.contributor.author |
Brugnoli, Roberto |
dc.date |
2017-06-01T14:53:00Z |
dc.date |
2017-06-01T14:53:00Z |
dc.date |
2016-02-23 |
dc.date |
2017-06-01T14:53:01Z |
dc.identifier.citation |
1176-6328 |
dc.identifier.citation |
667859 |
dc.identifier.uri |
http://hdl.handle.net/2445/111898 |
dc.format |
10 p. |
dc.format |
application/pdf |
dc.language.iso |
eng |
dc.publisher |
Dove Medical Press |
dc.relation |
Reproducció del document publicat a: https://doi.org/10.2147/NDT.S100675 |
dc.relation |
Neuropsychiatric Disease And Treatment, 2016, vol. 12, p. 383-392 |
dc.relation |
https://doi.org/10.2147/NDT.S100675 |
dc.rights |
cc-by-nc (c) Novick, Diego et al., 2016 |
dc.rights |
info:eu-repo/semantics/openAccess |
dc.rights |
http://creativecommons.org/licenses/by-nc/3.0/es |
dc.subject |
Depressió psíquica |
dc.subject |
Antidepressius |
dc.subject |
Serotonina |
dc.subject |
Àsia de l'est |
dc.subject |
Mental depression |
dc.subject |
Antidepressants |
dc.subject |
Serotonin |
dc.subject |
East Asia |
dc.title |
Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia |
dc.type |
info:eu-repo/semantics/article |
dc.type |
info:eu-repo/semantics/publishedVersion |
dc.description.abstract |
PURPOSE: To assess and compare the levels of functioning in patients with major depressive disorder treated with either duloxetine with a daily dose of ≤60 mg or a selective serotonin reuptake inhibitor (SSRI) as monotherapy for up to 6 months in a naturalistic setting in East Asia. In addition, this study examined the impact of painful physical symptoms (PPS) on the effects of these treatments. PATIENTS AND METHODS: Data for this post hoc analysis were taken from a 6-month prospective observational study involving 1,549 patients with major depressive disorder without sexual dysfunction. The present analysis focused on a subgroup of patients from East Asia (n=587). Functioning was measured using the Sheehan Disability Scale (SDS). Depression severity was assessed using the 16-item Quick Inventory of Depressive Symptomatology-Self Report. PPS were rated using the modified Somatic Symptom Inventory. A mixed model with repeated measures was fitted to compare the levels of functioning between duloxetine-treated (n=227) and SSRI-treated (n=225) patients, adjusting for baseline patient characteristics. RESULTS: The mean SDS total score was similar between the two treatment cohorts (15.46 [standard deviation =6.11] in the duloxetine cohort and 16.36 [standard deviation =6.53] in the SSRI cohort, P=0.077) at baseline. Both descriptive and regression analyses confirmed improvement in functioning in both groups during follow-up, but duloxetine-treated patients achieved better functioning. At 24 weeks, the estimated mean SDS total score was 4.48 (standard error =0.80) in the duloxetine cohort, which was statistically significantly lower (ie, better functioning) than that of 6.76 (standard error =0.77) in the SSRI cohort (P<0.001). This treatment difference was more apparent in the subgroup of patients with PPS at baseline. Similar patterns were also observed for SDS subscores (work, social life, and family life). CONCLUSION: Depressed patients treated with duloxetine achieved better functioning compared to those treated with SSRIs. This treatment difference was mostly driven by patients with PPS at baseline. |